Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2018

Open Access 01-12-2018 | Letter

Are we near to the end of the standard dose of micafungin?

Authors: Alexander Agrifoglio, Lucía Cachafeiro, Eva Herrero, Manuel Sánchez, Abelardo García de Lorenzo

Published in: Critical Care | Issue 1/2018

Login to get access

Excerpt

We have carefully read the study titled “Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients” [1] and congratulate the authors for such an interesting initiative. …
Literature
1.
Maseda E, Grau S, Luque S, et al. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients. Crit Care. 2018;22:94.CrossRefPubMedPubMedCentral
2.
García de Lorenzo A, Luque S, Grau S, et al. Comparative population plasma and tissue pharmacokinetics of micafungin in critically ill patients with severe burn injuries and patients with complicated intra-abdominal infection. Antimicrob Agents Chemother. 2016;60:5914–21.CrossRefPubMedPubMedCentral
3.
Grau S, Luque S, Campillo N, et al. Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. J Antimicrob Chemother. 2015;70:2854–61.CrossRefPubMed
4.
Jullien V, Azoulay E, Schwebel C, et al. Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation. J Antimicrob Chemother. 2017;72:181–9.CrossRefPubMed
Metadata
Title
Are we near to the end of the standard dose of micafungin?
Authors
Alexander Agrifoglio
Lucía Cachafeiro
Eva Herrero
Manuel Sánchez
Abelardo García de Lorenzo
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2018
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-018-2068-z

Other articles of this Issue 1/2018

Critical Care 1/2018 Go to the issue

Review

Aerosolized antibiotics for ventilator-associated pneumonia: a pairwise and Bayesian network meta-analysis

Research

Estimating severity of influenza epidemics from severe acute respiratory infections (SARI) in intensive care units

Research

Tracheal intubation in critically ill patients: a comprehensive systematic review of randomized trials

Commentary

Do we need new trials of procalcitonin-guided antibiotic therapy?

Review

Improving glycemic control in critically ill patients: personalized care to mimic the endocrine pancreas

Research

Microcirculatory perfusion disturbances in septic shock: results from the ProCESS trial